← Back to Search

Virus Therapy

Participants diagnoses with Esophageal, Gastric, or Gastro-esophageal Junction Cancer for Esophageal Cancer

Phase 2

Recruiting

Led By Yelena Janjigian, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Disease progression on one prior line of therapy for metastatic disease

Patients must have histologically or cytologically confirmed esophageal, gastric, or gastroesophageal junction adenocarcinoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial will give participants a combination of different medications based on how their disease is progressing.

Who is the study for?

This trial is for individuals with certain types of cancer affecting the stomach, esophagus, or where they join together. Specific details on who can join are not provided here, but typically participants would need to meet certain health standards and have a diagnosis that matches the trial's focus.Check my eligibility

What is being tested?

The study is testing a combination of treatments: agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel in patients with esophageal or gastric cancers. The timing of each treatment may vary based on individual patient needs.See study design

What are the potential side effects?

While specific side effects are not listed here, common ones for cancer treatments include fatigue, nausea, increased risk of infection due to weakened immune system responses from chemotherapy agents like paclitaxel.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has worsened after one treatment for its advanced stage.

Select...

My cancer is confirmed to be in the esophagus, stomach, or where they meet.

Select...

My cancer can be measured or evaluated for treatment response.

Select...

I am 18 years old or older.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

My cancer is in the esophagus, stomach, or where they meet and cannot be removed by surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Response Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants diagnoses with Esophageal, Gastric, or Gastro-esophageal Junction CancerExperimental Treatment5 Interventions

Participants with measurable disease and with evaluable disease as defined by RECIST v1.1 will be enrolled on this study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ramucirumab

2017

Completed Phase 3

~5050

Paclitaxel

2011

Completed Phase 4

~5380

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,860 Total Patients Enrolled

Yelena Janjigian, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

11 Previous Clinical Trials

892 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently able to participate in this ongoing trial?

"Indeed, the details on clinicaltrials.gov reveal that this investigation is actively seeking suitable participants. The study was initially shared on February 1st, 2024, and last revised on the same date. There are openings for 38 patients spread across seven different locations."

Answered by AI

Are individuals with esophageal, gastric, or gastroesophageal junction cancer eligible for treatment under FDA guidelines?

"Based on our assessment at Power, individuals diagnosed with Esophageal, Gastric, or Gastro-esophageal Junction Cancer have been rated a safety score of 2. This rating is determined by the existing data suggesting some level of safety but lacking evidence of effectiveness in this Phase 2 investigation."

Answered by AI

What is the largest group size allowed to enroll in this research study?

"Affirmative. The details on clinicaltrials.gov reveal that this investigation is actively seeking volunteers. Initially shared on February 1st, 2024, it was last revised on the same day. In total, the research seeks to enroll 38 participants from seven distinct locations."

Answered by AI

Are there numerous medical facilities in the city conducting this particular trial?

"There are 7 participating locations for this research, with Memorial Sloan Kettering Cancer Center in New york offering all protocol activities. Additionally, there are limited protocol activities available at Memorial Sloan Kettering Basking Ridge in Basking Ridge and at Memorial Sloan Kettering Monmouth in Middletown."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

2024. "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06251973.

All > Gastric Cancer